Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 197.58

0.0%

12:10 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (26675)	11/25/1998 1:41:00 PM
From: Machaon	Read Replies (2) of 32384

<< It is difficult to imagine anyone on a panel turning down a drug based on the panel members view of the market for the drug. >> I agree. Perhaps this shines some light on his reasoning that the skin irritation, caused by Panretin Gel, was more serious than curing the malignant cancerous KS lesions. That fact that patients, in the trials, wanted to continue using the gel, and continued to improve should bear a heavy weight on Panretin's value in treating KS. It would be interesting to know if the AIDS member of the panel had KS. I think that only a minority of AIDS patients get KS. Well....... tomorrow is Thanksgiving. I wonder if the FDA is meeting on Friday, the deadline for a decision on Panretin? Have a Happy Thanksgiving....... Bob

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next